Raises FY25 revenue view to $768M-$793M from $756M-$776M, consensus $769.64M. Sees FY25 adjusted EBITDA $195M-$205M.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals Files Proxy for 2025 Meeting
- ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ANI Pharmaceuticals presents preclinical data on use of Cortrophin Gel
- ANI Pharmaceuticals: Strategic Shift and Litigation Outcomes Poised to Drive Growth
- ANI Pharmaceuticals price target raised to $65 from $62 at Truist